Navigation Links
Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
Date:7/29/2009

CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three and six-month periods ended June 30, 2009.

"Clinical results from our monotherapy and combination clinical trials with REOLYSIN(R) continued to emerge in the second quarter," said Dr. Brad Thompson, President and CEO of Oncolytics. "The results of these trials, and the response and clinical benefit rates as reported by our investigators, reinforce our belief that REOLYSIN has the potential to significantly improve treatment outcomes in patients with a broad range of cancers."

Selected Second Quarter Highlights

    -   Presented updated U.S. Phase II sarcoma trial data at the American
        Society of Clinical Oncology (ASCO) annual meeting. The interim
        results demonstrated that the treatment was well tolerated, with 15
        of 36, or 42% of evaluable patients experiencing stable disease (SD)
        for more than 16 weeks, including five patients who had SD for more
        than 24 weeks. Patient enrolment was completed in May;

    -   Presented a poster at ASCO demonstrating that the combination of
        REOLYSIN and gemcitabine in a U.K. Phase I trial was well tolerated,
        and resulted in disease control for a majority of the patients. Of
        the ten patients evaluable for response, two patients (breast and
        nasopharyngeal) had partial responses (PRs) and/or clinical responses
        and five patients had SD for 4-8 cycles, for a total disease control
        rate (CR (Complete Response)+PR+SD) of 70%;

    -   Presented a poster at ASCO that indicated REOLYSIN was well tolerated
        and demonstrated anti-tumour activity in a U.S. Phase I systemic
        administration monotherapy trial. Of 18
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... It’s a hard truth: Nearly half of recent veterans who ... are failing to obtain a diploma or certificate within a ... an analysis by The Resume Place , a major ... college majors, which leads to underemployment, unemployment or just plain ... of post-9/11 veterans using GI Bill education benefits ...
(Date:7/28/2014)... DUBLIN , July 28, 2014 Research ... "Global Particle Size Analysis Market 2014-2018" report to their ... Particle size analysis is a technique used to determine ... powder or liquid. It is crucial to analyze the size ... material. Therefore, particle size analysis is performed to determine the ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... July 25, 2014 According to a ... Drugs Market - Global Industry Analysis, Size, Share, Growth, ... drugs market is estimated at USD 161,056.5 million in ... of 10.1% from 2014 to 2020, to reach an ... The biological drugs market is witnessing a significant growth ...
Breaking Biology Technology:Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Particle Size Analysis Market 2014-2018 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3
... Registry reveals that 70% of deaths in the stable stroke ... other than stroke, NICE, France, May 15 New ... Congress, highlight that among,those who die after a stroke the ... overall death rate is 4.45%, with,3.23% of these CV deaths ...
... , Chinese researchers have recently made a golden ... is a large ring-shaped molecule containing 36 gold atoms. The ... Universities of Beijing, Hong Kong, and Nanjing report their unusual ... is held together exclusively by goldgold bonds and is thus ...
... opportunities for micro and nano technologies. These challenges are ... the control and understanding of their behaviour. , This ... fibre analysis at the micro and nano-scale using state-of-the ... techniques. , Topics include fundamental effects of topography in ...
Cached Biology Technology:Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 2Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 3Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 4Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke 5Golden nanocrown 2Micro and Nano Scale Characterization of Fibers 2
(Date:7/28/2014)... suggests that the effects of a commonly used anesthetic ... , The study, published in this week,s issue of ... biologists at the University of California, San Diego and ... to concerns, arising from multiple studies on humans over ... may increase their susceptibility to long-term cognitive and behavioral ...
(Date:7/28/2014)... identified areas of the Earth that are high priorities ... Europe is particularly vulnerable, as it has the lowest ... of any continent in ,refugia, areas of biological ... remain relatively constant during times of great environmental change. ... in Scandinavia and Scotland. , The biggest refugia ...
(Date:7/28/2014)... that can help advance the genetic engineering of ... has been developed by researchers with the U.S. ... a multi-institutional partnership led by Lawrence Berkeley National ... an assay that enables scientists to identify and ... components in the biosynthesis of plant cell walls. ...
Breaking Biology News(10 mins):Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2How sweet it is 2How sweet it is 3
... aspires to a lifetime of addiction. But their brains ... journal Neuropsychopharmacology this week, Rockefeller University researchers ... can sustain lifelong and permanent changes in their reward ... and make such adolescents more vulnerable to the drug,s ...
... of Palm Vein Authentication Technology with, Single-Sign On Solutions ... ... Passwords, SUNNYVALE, Calif., Sept. 9 Fujitsu Computer ... products including,hard disk drives, peripherals and biometric security solutions, ...
... novel way to improve survival and recovery rate after ... Stem Cell Research by scientists at Singapore,s Institute ... and The Netherlands, University Medical Center Utrecht. ... the first non-cell based therapeutic application of human embryonic ...
Cached Biology News:Abuse of painkillers can predispose adolescents to lifelong addiction 2Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 2Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 3Fujitsu Announces PalmSecure(TM) LOGONDIRECTOR 4Human embryonic stem cell secretions minimized tissue injury after heart attack 2Human embryonic stem cell secretions minimized tissue injury after heart attack 3
EML1 (K-16)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
... ,• Eliminates nonspecific products due to ... specificity allows extension through DNA regions which ... Leaves an 'A' overhang ,TEMPase II ... DNA Polymerase that remains inactive at ...
Biology Products: